Novo Nordisk to Sell Wegovy on Hims & Hers Platform; HIMS Shares Surge 40%

Key Facts

1Novo Nordisk plans to sell its weight-loss drug Wegovy on the Hims & Hers Health platform.

2Hims & Hers (HIMS) shares surged nearly 40% in after-hours trading following the report.

3The partnership effectively ends a long-standing legal and commercial feud over copycat medications.

Novo Nordisk has reportedly entered into a strategic partnership with telehealth provider Hims & Hers Health to distribute its blockbuster weight-loss drug, Wegovy. The move marks a significant shift in strategy, effectively ending a long-standing legal and commercial dispute regarding patent infringement and compounded GLP-1 alternatives. Following the announcement, shares of Hims & Hers (HIMS) skyrocketed nearly 40% in after-hours trading, while Novo Nordisk (NVO) ADRs saw a modest gain of 2%. This collaboration allows Novo Nordisk to leverage Hims & Hers' extensive digital pharmacy network to reach a broader consumer base. For Hims & Hers, the deal provides a stable supply of branded medication amidst increasing regulatory scrutiny of compounded drug versions. Analysts view this development as a major win for both companies, resolving legal uncertainties and solidifying their positions in the high-growth obesity treatment market.